JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Vries, E. F.J.
Right arrow Articles by Vaalburg, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Vries, E. F.J.
Right arrow Articles by Vaalburg, W.
Journal of Nuclear Medicine Vol. 44 No. 10 1700-1706
© 2003 by Society of Nuclear Medicine


Basic Science Investigations

Synthesis and In Vivo Evaluation of 18F-Desbromo-DuP-697 as a PET Tracer for Cyclooxygenase-2 Expression

Erik F.J. de Vries, PhD, Aren van Waarde, PhD, Anne Rixt Buursma, MSc and Willem Vaalburg, PhD

PET Center, Groningen University Hospital, Groningen, The Netherlands

Cyclooxygenase-2 (COX-2) overexpression has been observed in various pathologies, such as inflammation, cancer, ischemia, and Alzheimer’s disease. As an initial step toward a noninvasive PET technique to assay COX-2 expression, this study describes the synthesis and preliminary evaluation of the radiolabeled COX-2 inhibitor 18F-desbromo-DuP-697. Methods: Desbromo-DuP-697 was radiolabeled by a nucleophilic aromatic substitution reaction of the nitro precursor with 18F-fluoride. Biodistribution studies of the tracer were performed in a carrageenan-induced hyperalgesia rat model. Brain uptake was investigated with autoradiography. To confirm the results of the biodistribution, COX activity was determined by a peroxidase assay. Results: Biodistribution studies showed specific binding of the tracer to COX-2 in heart, kidney, brain, and blood cells, but not in the inflamed paw, which was probably due to low COX-2 expression. In the brain, regional differences in tracer uptake were observed, with high uptake in cortical regions. 18F-Desbromo-DuP-697 did not show any binding to COX-1. Nonspecific uptake was high in fat and intestines. Conclusion: Because of its ability to cross the blood-brain barrier, 18F-desbromo-DuP-697 appears to be suitable for COX-2 imaging in the brain. Its high nonspecific uptake in the intestines may limit its use for imaging in the abdominal region.

Key Words: PET • desbromo-DuP-697 • cyclooxygenase-2 • inflammation • carrageenan




This article has been cited by other articles:


Home page
RadiologyHome page
S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir
Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice
Radiology, September 1, 2007; 244(3): 651 - 671.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Johansson, A. Rytkonen, H. Wan, P. Bergman, L. Plant, B. Agerberth, T. Hokfelt, and A.-B. Jonsson
Human-Like Immune Responses in CD46 Transgenic Mice
J. Immunol., July 1, 2005; 175(1): 433 - 440.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2003 by the Society of Nuclear Medicine.